TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Deepens AI-Driven R&D With Congruence Deal – A Strategic Shift?
Earlier in March 2026, Ono Pharmaceutical Co., Ltd. and Congruence Therapeutics expanded their drug discovery collaboration to cover neurology and immunology, giving Ono exclusive worldwide option rights over any resulting small molecule candidates and tying Congruence’s economics to upfront, milestone and tiered royalty payments.
This move extends Ono’s use of Congruence’s Revenir computational platform beyond oncology into areas of significant unmet medical need, potentially reshaping the...